Novartis on point in EU for asthma triple as CHMP backs EnerzairNovartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now Share XNovartis on point in EU for asthma triple as CHMP backs Enerzairhttps://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/
